These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 363629)

  • 1. Treatment of obesity: comparison of physician and nonphysician therapists using placebo and anorectic drugs in a double-blind trial.
    Atkinson RL; Greenway FL; Bray GA; Dahms WT; Molitch ME; Hamilton K; Rodin J
    Int J Obes; 1977; 1(2):113-20. PubMed ID: 363629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind trial of mazindol using a very low calorie formula diet.
    Baird IM; Howard AN
    Int J Obes; 1977; 1(3):271-8. PubMed ID: 363631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AN 448 Sandoz (Mazindol) in the treatment of obesity.
    Wallace AG
    Med J Aust; 1976 Mar; 1(11):343-5. PubMed ID: 775265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of the anorectic effect of mazindol and placebo in obesity].
    Tatoń J; Czech A; Koliński P; Podwysocka G
    Pol Tyg Lek; 1979 Dec; 34(50):1967-70. PubMed ID: 395517
    [No Abstract]   [Full Text] [Related]  

  • 5. Double blind clinical trial of mazindol on weight loss blood glucose, plasma insulin and serum lipids in overweight diabetic patients.
    Slama G; Selmi A; Hautecouverture M; Tchobroutsky G
    Diabete Metab; 1978 Sep; 4(3):193-9. PubMed ID: 361463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double blind controlled trial of a new anorectic agent AN448.
    Woodhouse SP; Nye ER; Anderson K; Rawlings J
    N Z Med J; 1975 Jun; 81(542):546-9. PubMed ID: 1099491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicentre study comparing mazindol and placebo in obese patients.
    Walker BR; Ballard IM; Gold JA
    J Int Med Res; 1977; 5(2):85-90. PubMed ID: 326596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative trial on the effects of diet, mazindol, and placebo in the treatment of exogenous obesity (author's transl)].
    Mies R
    Med Klin; 1976 Nov; 71(46):2013-6. PubMed ID: 995040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Slowed gastric evacuation accounts for the reduction of food intake by anorectic drugs.
    Jonderko K; Kucio C; Skrzypek D
    Eur J Clin Nutr; 1988 Jul; 42(7):627-31. PubMed ID: 3066620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three controlled trials of weight loss with phenylpropanolamine.
    Altschuler S; Conte A; Sebok M; Marlin RL; Winick C
    Int J Obes; 1982; 6(6):549-56. PubMed ID: 6761288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical trial with a nonamphetaminic anoretic].
    Campagnoli M
    Rev Iber Endocrinol; 1976; 23(137):463-83. PubMed ID: 794978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multi-centre general practice trial of mazindol in the treatment of obesity.
    Maclay WP; Wallace MG
    Practitioner; 1977 Mar; 218(1305):431-4. PubMed ID: 322112
    [No Abstract]   [Full Text] [Related]  

  • 13. Double-blind trial of mazindol in overweight patients.
    Heber KR
    Med J Aust; 1975 Oct; 2(14):566-7. PubMed ID: 1105106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind clinical evaluation of mazindol (42-548) in obese diabetics.
    Bandisode MS; Boshell BR
    Curr Ther Res Clin Exp; 1975 Dec; 18(6):816-24. PubMed ID: 813947
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clinical evaluation of Teronac (mazindol) in the treatment of obesity in children. Part II. Anorectic properties and side effects (author's transl)].
    Gołebiowska M; Chlebna-Sokół D; Kobierska I; Konopińska A; Małek M; Mastalska A; Zwaigzne-Raczyńska J
    Przegl Lek; 1981; 38(3):355-8. PubMed ID: 7017827
    [No Abstract]   [Full Text] [Related]  

  • 16. [Treatment of obesity with a non-amphetamine anorexigenic agent (author's transl)].
    Riesco J; Troncoso G; Costamaillere L; Rodríguez J
    Rev Med Chil; 1977 Jun; 105(6):375-9. PubMed ID: 331428
    [No Abstract]   [Full Text] [Related]  

  • 17. Double-blind cross-over evaluation of mazindol in the treatment of obese hypertensive patients.
    Miach PJ; Thomson W; Doyle AE; Louis WJ
    Med J Aust; 1976 Sep; 2(10):378-80. PubMed ID: 792640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Long-term treatment of patients with obesity using mazindol and a reducing diet].
    van Seters AP; Bouwhuis-Hoogerwerf ML; Goslings BM; van Nieuwkoop L; van Slooten H; Struijk-Wielinga T
    Ned Tijdschr Geneeskd; 1982 May; 126(22):990-4. PubMed ID: 7110390
    [No Abstract]   [Full Text] [Related]  

  • 19. Double-blind evaluation of mazindol in refractory obesity.
    Smith RG; Innes JA; Munro JF
    Br Med J; 1975 Aug; 3(5978):284. PubMed ID: 1097046
    [No Abstract]   [Full Text] [Related]  

  • 20. Double-blind evaluation of the effects of mazindol on pain, depression, anxiety, appetite, and activity in terminal cancer patients.
    Bruera E; Carraro S; Roca E; Barugel M; Chacon R
    Cancer Treat Rep; 1986 Feb; 70(2):295-8. PubMed ID: 3512080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.